FDA Grants IND Clearance for Imviva’s CTA313 Allogeneic CAR-T Therapy in Autoimmune Disease Treatment

The U.S. Food and Drug Administration has cleared Imviva Biotech‘s Investigational New Drug application for CTA313, allowing the company to... Read More

The post FDA Grants IND Clearance for Imviva’s CTA313 Allogeneic CAR-T Therapy in Autoimmune Disease Treatment appeared first on citybiz.